Open AccessDolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial
Author(s) -
Babafemi Taiwo,
Vincent C. Marconi,
Baiba Berzins,
Carlee Moser,
Amesika N. Nyaku,
Carl J. Fichtenbaum,
Constance A. Benson,
Timothy Wilkin,
Susan L. Koletar,
Jonathan Colasanti,
Edward P. Acosta,
Jonathan Z. Li,
Paul E. Sax
Publication year - 2017
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cix1131
Subject(s) - dolutegravir , medicine , lamivudine , randomized controlled trial , virology , clinical trial , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , virus , hepatitis b virus
NCT02263326.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom